|
AbbVie is a research-based biopharmaceutical company. Co. operates as a single business segment dedicated to the research and development, manufacturing, commercialization and sale of medicines and therapies. Co.'s products include: immunology products such as Humira, Skyrizi, and Rinvoq; oncology products such as Imbruvica and Venclexta/Venclyxto; aesthetics products such as Botox Cosmetic and The Juvederm Collection of Fillers; neuroscience products such as Botox Therapeutic, Vraylar, and Ubrelvy; eyecare products such as Lumigan/Ganfort, Alphagan/Combigan, and Restasis; women's health products such as Lo Loestrin and Orilissa/Oriahnn; and other key products such as Creon and Synthroid.
|
|
|
ABBV Next Dividend Date » (Projection based upon history) ABBV Dividend Growth Rate » Quotes delayed 20 minutes |
Buy (3.17 out of 4) 43rd percentile
(ranked lower than approx. 57% of all stocks covered)
Analysts' Target Price: ABBV Forecast Based on data provided by Zacks Investment Research via Quandl.com |
Projection:
ABBV Next Dividend Date |